ProciseDx wins CE Mark for point-of-care tests

2019 05 18 00 32 7363 Blood Cells 200

Nestlé Health Science subsidiary ProciseDx has received the European CE Mark for Procise IFX and Procise ADL, the company's infliximab and adalimumab point-of-care diagnostics.

Procise IFX and Procise ADL provide diagnostic data for therapeutic drug monitoring within five minutes of a finger-prick blood sample, the company noted. Both tests run on the ProciseDx system, which is about the size of a shoe box.

Page 1 of 10
Next Page